Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis
Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Sydney Kwiecien, Melissa MacDonald, Bo Gao, Mariam A. Mamai, Chao Lu, Urooj F. Bajwa, Nikhil Uppal, James C. Fredenburgh, Masao Kakoki, Salvatore V. Pizzo, Anthony F. Rullo, Matthew B. Lanktree, Jeffrey I. Weitz, Yaseelan Palarasah, Joan C. Krepinsky
Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Sydney Kwiecien, Melissa MacDonald, Bo Gao, Mariam A. Mamai, Chao Lu, Urooj F. Bajwa, Nikhil Uppal, James C. Fredenburgh, Masao Kakoki, Salvatore V. Pizzo, Anthony F. Rullo, Matthew B. Lanktree, Jeffrey I. Weitz, Yaseelan Palarasah, Joan C. Krepinsky
View: Text | PDF
Research Article Nephrology Therapeutics

Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis

  • Text
  • PDF
Abstract

We recently showed that cell surface translocation of the endoplasmic reticulum–resident protein GRP78, when bound by activated α 2-macroglobulin (α2M*), induces pro-fibrotic responses in glomerular mesangial cells in response to high glucose and regulates activation of the pro-fibrotic cytokine transforming growth factor-β1 (TGF-β1), implicating a pathogenic role in glomerulosclerosis. Interstitial fibrosis, largely mediated by proximal tubular epithelial cells (PTEC) and renal fibroblasts, develops later in kidney disease and correlates with functional decline. Here we investigated whether interstitial fibrosis was mediated by cell surface GRP78 (csGRP78)/α2M*. High glucose and TGF-β1 increased csGRP78 and α2M* in PTEC and renal fibroblasts, and their inhibition prevented fibrotic protein production. Interestingly, for TGF-β1, this depended on inhibition of noncanonical signaling through YAP/TAZ, with Smad3 activation unaffected. In vivo, type 1 diabetic Akita mice overexpressing TGF-β1 were treated with either a neutralizing antibody for csGRP78 (C38) or α2M* (Fα2M) or an inhibitory peptide blocking csGRP78/α2M* interaction, and mice with unilateral ureteral obstruction were treated with Fα2M or inhibitory peptide. Consistently, inhibition by antibody or peptide attenuated fibrosis and pro-fibrotic signaling. These findings show an important role for csGRP78/α2M* in mediating tubulointerstitial fibrosis in both diabetic and nondiabetic kidney disease and support their inhibition as a potential antifibrotic therapeutic intervention.

Authors

Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Sydney Kwiecien, Melissa MacDonald, Bo Gao, Mariam A. Mamai, Chao Lu, Urooj F. Bajwa, Nikhil Uppal, James C. Fredenburgh, Masao Kakoki, Salvatore V. Pizzo, Anthony F. Rullo, Matthew B. Lanktree, Jeffrey I. Weitz, Yaseelan Palarasah, Joan C. Krepinsky

×

Figure 1

Inhibition of csGRP78 or α2M* prevents high glucose–induced matrix production in PTEC and renal fibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of csGRP78 or α2M* prevents high glucose–induced matrix produ...
High glucose– (6 or 24 hours, 30 mM) induced csGRP78 expression, assessed by biotinylation, was increased in (A) PTEC (n = 6) and (B) renal fibroblasts (n = 3). Production of α2M (24 and 48 hours) by PTEC (C) and renal fibroblasts (D) was increased by high glucose (30 mM, n = 5 and 8, respectively). Similar results were observed for α2M activation (E and F, respectively) (high glucose 48 hours, 30 mM, n = 5 and 4, respectively). Inhibition of csGRP78 interaction with α2M* using the GRP78-targeting antibody C38 prevented high glucose– (30 mM, 48 hours) induced fibronectin and collagen IV production in both (G) PTEC (n = 4–6) and (H) renal fibroblasts (n = 3–5). Similarly, α2M* inhibition with the Fα2M antibody attenuated matrix protein production in high glucose (30 mM, 48 hours, n = 5–6 PTEC and 4 renal fibroblasts (I = PTEC and J = renal fibroblasts). Peptide inhibition of the csGRP78/α2M* interaction also prevented matrix protein production in high glucose (30 mM, 48 hours) by (K) PTEC (n = 4–9) and (L) renal fibroblasts (n = 3–6) (*P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts